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agement in the TACTICS-TIM118 trial. Decision-limits of 80 pg/ml for SNP and 0.1 ng/ml 
for cTnl were pre-specified based on prior work. RESULTS: Pts with baseline BNP > 80 
ng/ml (n = 310) were at significantly higher risk of death by 30 days (5,2 vs. 1.2%, 
p<0.00Of) and 6 months (8.7 vs. 1.7%, p<0.0O01) after presentation. BNP predicted 
mortality independently of age, ST-segment depression, cTnl result, history of CHF and 
Killip class at presentation (p<0.0001). Importantly, BNP identified patients with negative 
oTnl who were at high risk for death (p=0.004) and death/MI (p=0.008) [FIG]. There was 
no significant difference in the benefit of INV vs. CON therapy among pts with positive vs. 
negative BNP with respect to deatWMI at 30 and 180 days (p-interaction >0.5). CON- 
CLUSIONS: BNP adds complementary information to cardiac troponin for risk assess- 
ment in unstable angina/non-ST elevation MI. Future research should aim at 
interventions which may reduce the risk associated with increased BNP. 
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The Inter-Relationship Between Creatinine Clearance, 
Cardiac Troponin T And Outcomes in Patients With 
Acute Coronary Syndromes 
Ronnier J. Aviles. Arman T. Askari, E. Magnus Ohman, Kenneth W. Mahaffy, L. Kristin 
Newby, Peter Berger, Gang Jia, Robert M. Califf, Bertil Lindahl, Lars Wallentin, Eric J. 
Topoi, Michael S. Lauer, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Although abnormal cardiac troponin T (TnT) is predictive of poor outcome, 
the prognostic value of cardiac troponin T in patients with renal impairment remains contro- 
versial. 
Methods: In GUSTO IV, 7800 with ACS were randomized to treatment with placebo, abcix- 
imab for 24 hours, or abciximab for 48 hours. The study cohort comprised 7637 subjects 
with complete TnT, creatinine clearance (CCI), and clinical data. Baseline TnT and CCI 
were analyzed. CCI was evaluated as categorical and as a continuous variable. Abnormal 
TnT: TnT > 0.1 mg/dL; abnormal CCI: CCI < median CCI (76 ml/min.). End point: composite 
of 30-day death and MI. 
Results: Death/MI occurred in 648 subjects. There were 126 (6%) events in patients with 
abnormal TnT, 140 (8%) events in patients with abnormal CCI, and 311 (15%) in subjects 
with both abnormal TnT/CCI. The highest risk of death/MI occurred in patients with both 
abnormal TnT/CCI (OR, 4.4; 95% CI, 3.4 - 5.7; P < 0.001), suggesting that abnormal TnT is 
predictive of outcome in patients with abnormal CCI. Even after adjusting for age > 65 yrs, 
weight > 90 kg, ST depression, history of angina, MI, CHF, diabetes, hyperlipidemia, HTN, 
smoking, PCI, CABG, stroke, and treatment with lib/Ilia, patients with both abnormal TnT/ 
CCI had the highest risk of death/MI (OR, 3.3; 95% CI, 2.5 - 4.5; P < 0.001). TnT was pre- 
dictive of outcome across the entire spectrum of CCI (Figure 1 ). 
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Conclusion: The prognostic value of TnT is not decreased in patients with impaired renal 
function who present with suspected ACS. 
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822-6 Elevated Serum Myoglobin Is Associated With 
Increased Long-Term Mortality, Independent of Cardiac 
Troponin I, Electrocardiographic Variables, and Other 
Baseline Variables: Combined Analyses From TIM111B 
and TACTICS/TIM118 
James A. de I._emos. David A. Morrow, Michael Gibson, $abina A. Murphy, Nader Rifai, 
Mark S. Sabatine, Howard A. Cooper, Carolyn H. McCabe, Elliott M. Antman, 
Christopher P. Cannon, Eugene Braunwald, University of Texas Southwestern Medical 
School, Dallas, Texas, TIMI Study Group, Boston, Massachusetts. 
Myoglobin (MYO) is a sensitive, but nonspecdic early marker of myocardial injury. Few 
studies have considered the prognostic implications of increased MYO among pts with 
non-ST elevation acute coronary syndromes (ACS). 
Methods: Baseline levels of MYO, cTnl, and CKMB were measured in 616 pts from TIMI 
11B and 1841 pts from TACTICS/TIMI t 8 (ACS:180, Bayer Diagnostics). Mortality at 6 
months was compared between pts with MYO levels above and below the recommended 
diagnostic threshold (110 ~g/L). 
Results: Pts with elevated baseline MYO were older, more often male, and more likely to 
present with MI (vs unstable angina), ECG changes, increased CKMB and increased 
cTnl (p<0.01 for each variable). In multivariate analyses adjusting for index diagnosis, 
baseline variables, ECG changes, cTnl, and CKMB, elevated baseline MYO remained 
associated with higher 6-month mortality: TIMI 11B adjusted OR 2.9 [1.2-7.0]; TACTICS/ 
TIMI 18 adjusted OR 2.7 [1.4-5.2]; combined dataset adjusted OR 2.8 [1.7-4.7]. There 
was no consistent association between MYO and nonfatal MI or recurrent ischemic 
events. 
Conclusions: In two distinct groups of pts with ACS, elevated baseline myoglobin was 
associated with a statistically significant near 3-fold increase in the risk for long-term mor- 
tality, independent of other baseline risk predictors, including age, diabetes, ECG 
changes and biomarkers such as cTnl and CKMB. These findings suggest that myoglo- 
bin should be added to the panel of biomarkere routinely measured in pts with ACS. 
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828 Enhancing Fibrinolysis: Combination 
With Newer Antiplatelet and 
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828-1 Prevention of Reinfarction Using Half-Dose Reteplase 
and Abciximab: Observation From the GUSTO-5 Trial 
E. Maanus Qhman, Robert M. Califf, Michael Lincoff, Paul Armstrong, Neal Kleiman, 
Judith Hochman, Harvey White, Stefano Savonifto, Marion Piedmonte, Joan Booth, Eric 
J. Topoi, The University of North Carolina, Chapel Hill, North Carolina, The Cleveland 
Clinic Foundation, Cleveland, Ohio. 
Background: An important caveat to successful reperfusion in acute myocardial infarction 
has been reinfarction occudng early after administration of fibrinotytic therapy. Reinfarc- 
tions are associated with major morbidity and a high mortality. The impact of newer com- 
bination reperfusion therapies on reinfarction rates remains to be determined. Methods: 
We examined the rate of reinfarction among patients randomized to either r-PA (10+10u) 
or low-dose r-PA (5+5u) and full dose abciximab in the GUSTO-5 trial. Results: A total of 
479 patients (2.9%) had a reinfarction through discharge or 7 days, whichever was 
sooner. Patients randomized to combination therapy had significantly lower rate of reinf- 
arction compared with r-PA alone (2.3% vs 3.5%, p<O.0001). Reinfarctions within the first 
24 hours of randomization were more common among patients treated with r-PA (29% of 
all patients with reinfarctions after r-PA) compared with combination therapy (19%). Cer- 
tain baseline characteristics were more common among patients with reinfarction versus 
those without, such as the elderly (over 75 years: 19% vs 13%), females (30% vs 25%), 
and in patients with prior MI (24% vs 15%), but less common among current smokers 
(33% vs 46%). In an adjusted analysis, patients randomized to combination therapy were 
less likely to suffer reinfarction (Odds Ratio: 0.67 95%Ch 0.56-0.80, p<0.001) compared 
to r-PA alone, even among patients who were more likely to have reinfarction such as 
older patients (p<O.O01), and those with previous M I (p<0.O01). Conclusions: Combina- 
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tion therapy with half-dose r:PA and abciximab reduces the rate of reinfarction across a 
broad range of patients compared with r-PA alone. The long-term implications of these 
findings on 1-year mortality awaits definition. 
2:15 p.m. 
828-2 The Abciximab ST-Recovery ON AMI (ASTRONAMI) 
GUSTO V Substudy: Enhanced Early Speed, Stability, 
and Quality of Reperfueion With AntI-Platelet 
Augmented Thrombolytic Therapy for ST-Elevation AMI 
Mitchell W. Krucoff, Cynthia L. Green, Anatoly Langer, Brian Giblet, Paul W. Armstrong, 
Kathleen M. Trollinger, Suzanne W. Crater, Michael A. Lincoff, Robert M, Califf, Eric J, 
TOpoI, The ASTRONAMI-GUSTO V Investigators, Duke University Medical Center~Duke 
Clinical Research Institute, Durham, North Caro/ina, Cleveland Clinic Foundation, 
C/eve/and, Ohio. 
Background: In the GUSTO V study combined Rx with abciximab and low dose rPA was 
compared to full dose rPA alone in pts with ST elevation MI. Modality with Combo Rx 
was non-inferior, Mechanistic differences were not reported. 
Methods: In the ASTRONAMI substudy the speed, stability and microvascular quality of 
reperfusion were quantified by blinded core lab analysis of ST recovery from Rozinn 152 
continuous digital 12-lead ECG recordings as: 1 ) time (minutes) from onset of Rx to a) 1st 
50% ST recovery from peak (1 st 50% ST} and b) >4 hrs with >50% ST recovery (STA- 
BLE ST); 2) recurrent ischemia (RE-ST, as % of pts with ST re-elevation >150uV over 
recovery levels; and 3) ST level vs. time trend curve area (ST AREA in uV-min), respec- 
tively. 
Results: A total of 4,992 pt hrs of monitoring totaling 299,520 ECGs were analyzed from 
207 pts (108 Combo Rx, 99 rPA Rx). Clinical descriptors, time from chest pain to Rx, time 
to ST monitoring, duration of monitoring and peak ST levels were comparable. ST recov- 
e~ results were: 
Descriptor rPA Rx Combo Rx P value* 
1 =t 50=/= ST (%) 46 (19.0, 92.6) 34.0 (0, 66) .042 
STABLE ST (min) f 00 (42, 162) 65 (0, 112) .002 
RE-ST (%) 40.2 30.1 . f 55 
ST AREA (uV-min) 4782 (259, 9820) 2576 (0, 7716) .047 
* continuous variables: two-sample t-test, Wilcoxon rank sum test; discrete variables: 
likelihood ratio chi-square, Fisher's exact text. 
Conclusion: Thus, combined Rx with abciximab and low dose rPA improves the speed, 
stability and microvascutar quality of reperfusion in ST-elevation MI compared to rPA 
alone. 
2:30 p.m. 
828-3 Combination Tenecteplase and Abciximab Results in 
More Complete ST Resolution: Findings from the 
ASSENT 3 ECG Subatudy 
Yulina Fu, Galen Wagner, Shaun Goodman, Frans Van de Werf, Christopher B. Granger, 
Paul W. Armstrong, for the ASSENT 3 Investigators, University of A/berta, Edmonton, 
A/berta, Canada. 
The ASSENT 3 study documented that the two experimental arms i.e. combination 
tenectsplase plus enoxaparin or half-dose tenecteplase and abciximab reduced the fre- 
quency of ischemic complications of acute myocardial infarction. The mechanism(s) for 
this benefit is unclear but combination therapy with fibrinolytic and glycoprotein lib/Ilia 
inhibitors has previously achieved more effective early reperfusion in phase 2 anglo- 
graphic trials whereas angiographic evaluation with low molecuJar weight heparin has 
shown less reocclusion. 
Accordingly we analyzed sequential ECG's at baseline, 60 and 180 minutes after enroll- 
ment in all patients in the ASSENT 3 study, in order to evaluate the 3 treatment groups 
(tenecteplase and enoxaparin [TNK/ENOX]; half dose tenecteplase and abciximab [1/2 
TNK/ABCX]; tanecteplase and unfractionated heparin [TNK/UH]). Amongst the 75% of 
the 6,095 patients who had technically suitable ECG data free of confounding factors, ST 
resolution compared to baseline is shown in the table, 
These data, in a large comprehensively studied AMI population, suggest better early 
myocardial perfusion with combination TNK-abciximab than TNK with either ENOX OR 
UH alone. They also suggest the clinical benefit of enoxaparin in ASSENT 3 is modu- 
lated by a mechanism different han early repertusion occurring later in the ischemic pro- 
cess. 
TNK/ENOX 1/2 TNK/ABCX TNK/UH 
60 min ECG n=1,506 n=1,472 n=1,483 
>=70% resolution 28.9 33.4* 31.9 
30-70% resolution 33.9 32.5 31.4 
<30% resolution 37.3 34.1 36.7 
180 min ECG n=1,463 n=1,461 n=1,416 
>=70% resolution 50.0 59.1 ** 48.0 
30-70% resolution 32.5 29.6 31.5 
<30% resolution 17.5 t 1.3 20.5 
*p=0.02 **p<0.001 
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828-4 Differential Impact of Antlthrombotlc Treatments 
Combined With Tenecteplaae in the Elderly With Acute 
Myocardial Infarction: Results From ASSENT-3 
Christooher B. Granoer. John H. Alexander, Emmanuel Lesaffre, Lars Wallentin, Paul W. 
Armstrong, Frans Van de Werf, Duke C/in/ca/Research Institute, Durham, North 
Carolina, Leuven Coordinating Centre, Leuven, Belgium. 
Background: Among patients with acute myocardial infarction (MI), the elderly are at par- 
ticularly high risk for death and bleeding complications, including with more aggressive 
antithrombotic strategies. 
Methods: In order to provide insight into risk and benefit in the elderly, we examined 
patients from the ASSENT-3 Trial with ST elevation MI, who were treated with tenect- 
eplase (TNK) and randomized to unfractionated heparin (UFH), enoxapadn, or abcix- 
imab with low dose heparJn (and half-dose TNK), 
Results: Of the 6095 patients enrolled, 13% (767) were >75 years of age. Compared to 
younger patients, patients > 75 had higher rates of death (17.9 vs 4.3%), intracraniat 
hemorrhage (ICH, 1.6 vs 0.8%), and bleeding. Older patients had higher rates of the effi- 
cacy + safety composite (death, reMI, refractory ischemia, ICH, and major bleeding) with 
abciximab than with enoxaparin or UFH (table), and the treatment effect of abciximab vs 
UFH was significantly less in older than in younger patients (interaction p<0.05). 
Conclusions: Elderly patients with acute MI are at high risk of death and bleeding, 
Although TNK with either enoxaparin or abciximab appeared to be more effective than 
with standard UFH in younger patients, TNK with abciximab as dosed in this trial was sig- 
nificantly less effective and may be unsafe in the elderly. For elderly patients, develop- 
ment of treatments with greater safety and effectiveness remains a high priority. 
>75 years (11=767) 
UHF Enoxaparin Abciximab p 
Death, reMI, refractory ischemia, ICH, 28.0 25.5 36.9 0.01 
major bleed (%) 
30-day death (%) 15.9 18.6 22.3 0.11 
ReMI (%) 6.3 2.3 3.0 0.07 
Major bleeding (%) 4.1 7.2 13.3 0.001 
ICH (%) 0.74 1.52 2.58 0.26 
3:00 p.m. 
828-5 Lack of Improvement in ST Segment Resolution After 
the Combination Treatment of Abcixlmab With 
Reteplase Compared to Reteplase Alone for Acute 
Myocardial Infarction: Results From the GUSTO V- 
RESTART Subatudy 
Femando A. Cure, Marco Roffi, Narcis Pasca, Katherine E. Wolski, Eric J. Topoi, Michael 
S. Lauer, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: The combination of abciximab during reperfusion therapies is believed to 
enhance tissue level and microvascular perfusion. Resolution of ST-segment elevation 
after administration of thrombolytic therapy in patients with acute myocardial infarction is 
a marker of myocardial reperfusion and has an important predictive value of mortality. 
This study compared the extent of 60-minute ST-segment elevation resolution of patients 
treated with full dose of reteplase versus half-dose reteplase in combination with abcix- 
imab given at the normal dose from the GUSTO V-AMI trial. 
Methods: From a total of 16.588 patients enrolled in the GUSTO V-AMI trial, 1764 were 
prospectively included in the RESTART substudy and were randomized to the combina- 
tion of full dose abciximab and half dose of reteplase or full dose of reteplase alone. A 
baseline and 60-minute ECG was analyzed by a core lab to categorize 4 groups: com- 
plete resolution (>70%), partial resolution (<70%-30%), no resolution (<30%) and wors- 
ening ST-segment. 
Results: There was no difference in the clinical baseline variables between the two treat- 
ment groups, The results are summarized in the table. 
Reteplase Reteplase + Abciximab p value 
(n=871) (n=893) 
Complete Resolution (%) 32 34 0.37 
Partial Resolution (%) 29 27 0.35 
No Resolution (%) 19 18 0.59 
Worsening ST-segment (%) 20 20 0.95 
30-day Mortality (%) 5.1 4.7 0.73 
Conclusion: Patients treated with reduced doses of reteplase when administered in 
combination with abciximab are associated with similar extent of ST-segment elevation 
resolution as those treated with full dose reteplase alone. 
3:15 p.m. 
828-6 Risk and Benefit of  Half-Dose Lytlc Plus Abciximab 
Versus Lytic Alone for ST-Elevation Myocardial 
Infarction: A Mate-Analysis 
Freak W. Verheuat. University Medical Center Nijmegen, Nijmegen, The Netherlands. 
Background Angiogrephic trials have shown improved 60 and 90 minutes coronary 
patency with half-dose lytic plus abciximab versus lytic alone in ST-elevation MI (STEMI). 
These strategies have recently been evaluated in 2 phase III msgatrials for efficacy and 
